Zydus Cadila gets USFDA nod for Empagliflozin & Linagliptin tablets
Zydus Cadila gets USFDA nod for Empagliflozin & Linagliptin tablets

Zydus Cadila gets USFDA nod for Empagliflozin & Linagliptin tablets

DSIJ Intelligence Article rating: 4.5

Zydus Cadila informed the exchanges on Wednesday that it has received tentative approval from United States Food & Drug Administration (USFDA) to market Empagliflozin and Linagliptin tablets (US RLD: Glyxambi tablets) in the strengths of 10 mg/5 mg and 25 mg/5 mg.

Gold prices decline by almost 8 per cent in a month
Gold prices decline by almost 8 per cent in a month

Gold prices decline by almost 8 per cent in a month

DSIJ Intelligence Article rating: 4.7

During Wednesday’s trading session, gold prices slipped again as profit booking was seen across equities. Sensex was in negative territory, down by more than 300 points.

India auto unit sales likely to decline by at least 30 per cent in 2020
India auto unit sales likely to decline by at least 30 per cent in 2020

India auto unit sales likely to decline by at least 30 per cent in 2020

Nidhi Jani Article rating: 5.0

On the other side, the global automotive industry's outlook has been changed to stable from negative. It said that the stable outlook for the global automotive industry reveals growing sales through 2021, with continued but slow increase through 2023.

Indian GDP to contract 10.5 per cent: Fitch Ratings
Indian GDP to contract 10.5 per cent: Fitch Ratings

Indian GDP to contract 10.5 per cent: Fitch Ratings

Amir Shaikh Article rating: 4.7

Fitch Ratings in its latest report has sharply lowered its forecast for India's gross domestic product (GDP) growth for the current fiscal year (FY21) to -10.5 per cent from -5 per cent estimated earlier

Buzzing stock: AstraZeneca Pharma crashes by more than 11 per cent
Buzzing stock: AstraZeneca Pharma crashes by more than 11 per cent

Buzzing stock: AstraZeneca Pharma crashes by more than 11 per cent

DSIJ Intelligence Article rating: 4.3

On Wednesday, the stock of AstraZeneca Pharma India tumbled by more than 11 per cent on BSE. The company’s parent company AstraZeneca PLC issued a statement stating that the standard review process has triggered a pause to the clinical trial of its COVID-19 vaccination to allow the review of safety data.

Dr Reddys Laboratories announces launch of 2 separate products in Indian & US market
Dr Reddys Laboratories announces launch of 2 separate products in Indian & US market

Dr Reddys Laboratories announces launch of 2 separate products in Indian & US market

DSIJ Intelligence Article rating: 4.3

Dr Reddy’s Laboratories Ltd announced the launch of Remdesivir along with its subsidiaries on Wednesday. The product is being launched under the brand name of Redyx in India. Additionally, it also announced the launch of over-the-counter (OTC) Diclofenac Sodium Topical Gel 1 per cent, the store brand version of Voltaren® Arthritis Pain in the US market.

Multibagger stock: Can Kingfa Science get its Mojo back?
Multibagger stock: Can Kingfa Science get its Mojo back?

Multibagger stock: Can Kingfa Science get its Mojo back?

DSIJ Intelligence Article rating: 3.6

The company will be conducting its 36th annual general meeting (AGM) on September 29, 2020. The stock has generated returns of 29 per cent on an annualised basis in the past 10 years. However, since the last three years, the stock has underperformed heavily, generating negative of 15.30 per cent on an annualised basis.

RSS
First28432844284528462848285028512852Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR